Treatment with this BCL2-inhibitor resulted in significantly more cell growth inhibition (Figure 5G) and cell death (Figure 5H) in CKS1B-transfected cells compared with EV-transfected cells, indicating that myeloma cells with higher CKS1B-expression are more sensitive to BCL2 inhibition than cells with lower CKS1B-expression. The gene discussed is BCL2; the disease is plasma cell myeloma.